Neuromyelitis Optica: A New Perspective

ABSTRACT

The traditional view of neuromyelitis optica (NMO) as a monophasic inflammatory disorder that affects both the optic nerves and the spinal cord is expanding. Over the last decade, a combination of clinical, radiological, pathological, and serological findings have resulted in evolving definitions of NMO and the appreciation that it likely constitutes a broader, more diverse spectrum of disease that is pathogenically distinct from multiple sclerosis. Neuromyelitis optica-immunoglobulin (Ig)G is the first antibody marker for any inflammatory central nervous system disorder, and is both sensitive and specific for NMO. Its target antigen, aquaporin-4, the most abundant water channel in the central nervous system, has opened up new research directions into demyelinating disorders of the central nervous system. The identification of NMO-IgG in patients with recurrent optic neuritis or longitudinally extensive myelitis and its ability to predict subsequent relapse support the concept of a spectrum of NMO disorders. Preliminary in vitro studies and recent immunopathological evidence support a role for NMO-IgG as the initiator of the NMO lesion. Definitive proof of pathogenesis is needed and will require the development of active immunization and passive transfer animal models, which will hopefully lead to more effective targeted therapies.

KEYWORDS

Neuromyelitis optica - Devic's disease - aquaporin - transverse myelitis - optic neuritis

REFERENCES

• 1 Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.  Ann Neurol. 2000;  47 707-717
• 2 Wingerchuk D M, Lennon V A, Pittock S J et al.. Revised diagnostic criteria for neuromyelitis optica.  Neurology. 2006;  66 1485-1489
• 3 Devic E. Myelite subaiguë compliquée de névrite optique.  Bull Med. 1894;  8 1033-1034
• 4 Wingerchuk D M, Hogancamp W F, O'Brien P C, Weinshenker B G. The clinical course of neuromyelitis optica (Devic's syndrome).  Neurology. 1999;  53 1107-1114
• 5 Lucchinetti C F, Mandler R N, McGavern D et al.. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.  Brain. 2002;  125 1450-1461
• 6 Lennon V A, Wingerchuk D M, Kryzer T J et al.. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.  Lancet. 2004;  364 2106-2112
• 7 Lennon V A, Kryzer T J, Pittock S J et al.. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.  J Exp Med. 2005;  202 473-477
• 8 Pittock S J, Lennon V A, Krecke K et al.. Brain abnormalities in neuromyelitis optica.  Arch Neurol. 2006;  63 390-396
• 9 Misu T, Fujihara K, Nakamura M et al.. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report.  Tohoku J Exp Med. 2006;  209 269-275
• 10 Roemer S F, Parisi J E, Lennon V A et al.. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.  Brain. 2007;  130 1194-1205
• 11 Kira J. Multiple sclerosis in the Japanese population.  Lancet Neurol. 2003;  2 117-127
• 12 McAlpine D. Familial neuromyelitis optica: its occurrence in identical twins.  Brain. 1938;  430-438
• 13 Ch'ien L T, Medeiros M O, Belluomini J J et al.. Neuromyelitis optica (Devic's syndrome) in two sisters.  Clin Electroencephalogr. 1982;  13 36-39
• 14 Yamakawa K, Kuroda H, Fujihara K et al.. Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan.  Neurology. 2000;  55 318-320
• 15 Keegan M, Weinshenker B. Familial Devic's disease.  Can J Neurol Sci. 2000;  27 S57-S58
• 16 Yamasaki K, Horiuchi I, Minohara M et al.. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies.  Brain. 1999;  122(Pt 9) 1689-1696
• 17 O'Riordan J I, Gallagher H L, Thompson A J et al.. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.  J Neurol Neurosurg Psychiatry. 1996;  60 382-387
• 18 de Seze J, Lebrun C, Stojkovic T et al.. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis.  Mult Scler. 2003;  9 521-525
• 19 Ghezzi A, Bergamaschi R, Martinelli V et al.. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica.  J Neurol. 2004;  251 47-52
• 20 Barbieri F, Buscaino G A. Neuromyelitis optica in the elderly.  Acta Neurol (Napoli). 1989;  11 247-251
• 21 Jeffery A R, Buncic J R. Pediatric Devic's neuromyelitis optica.  J Pediatr Ophthalmol Strabismus. 1996;  33 223-229
• 22 Wingerchuk D M, Pittock S J, Lucchinetti C F et al.. A secondary progressive clinical course is uncommon in neuromyelitis optica.  Neurology. 2007;  68 603-605
• 23 Mandler R N, Ahmed W, Dencoff J E. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.  Neurology. 1998;  51 1219-1220
• 24 Milano E, Di Sapio A, Malucchi S et al.. Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse.  Neurol Sci. 2003;  24 130-133
• 25 McDonald W I, Compston A, Edan G et al.. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis.  Ann Neurol. 2001;  50 121-127
• 26 de Seze J, Stojkovic T, Ferriby D et al.. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.  J Neurol Sci. 2002;  197 57-61
• 27 Bergamaschi R, Tonietti S, Franciotta D et al.. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations.  Mult Scler. 2004;  10 2-4
• 28 Ebers G C, Paty D W. CSF electrophoresis in one thousand patients.  Can J Neurol Sci. 1980;  7 275-280
• 29 McLean B N, Luxton R W, Thompson E J. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index: a comparison and diagnostic applications.  Brain. 1990;  113 1269-1289
• 30 Nakashima I, Fujihara K, Fujimori J et al.. Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica.  Neurology. 2004;  62 144-146
• 31 Ishizu T, Osoegawa M, Mei F J et al.. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis.  Brain. 2005;  128 988-1002
• 32 Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica.  Neurology. 2004;  63 2363-2370
• 33 Narikawa K, Misu T, Fujihara K et al.. Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica.  J Neurol. 2006;  253 111-113
• 34 Weinshenker B G, Wingerchuk D M, Vukusic S et al.. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.  Ann Neurol. 2006;  59 566-569
• 35 Scott T F, Kassab S L, Pittock S J. Neuromyelitis optica IgG status in acute partial transverse myelitis.  Arch Neurol. 2006;  63 1398-1400
• 36 Vernant J C, Cabre P, Smadja D et al.. Recurrent optic neuromyelitis with endocrinopathies: a new syndrome.  Neurology. 1997;  48 58-64
• 37 Poppe A Y, Lapierre Y, Melancon D et al.. Neuromyelitis optica with hypothalamic involvement.  Mult Scler. 2005;  11 617-621
• 38 Pittock S J, Weinshenker B G, Lucchinetti C F, Wingerchuk D M, Corboy J R, Lennon V A. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.  Arch Neurol. 2006;  63 964-968
• 39 Zuliani L, Blanco Y, Tavolato B et al.. Neuromyelitis optica autoantibody (NMO-IgG) in patients with suspected NMO or limited forms of NMO.  Mult Scler. 2006;  12 S155
• 40 Papeix C, Deseze J, Pierrot-Deseilligny C et al.. French therapeutic experience of Devic's disease: a retrospective study of 33 cases.  Neurology. 2005;  64 A328
• 41 Jarius S, Franciotta D, Bergamaschi R et al.. NMO-IgG in the diagnosis of neuromyelitis optica.  Neurology. 2007;  68 1076-1077
• 42 Akman-Demir G, Mutlu M, Icoz S et al.. Probable NMO IgG in Turkish patients with Devic's disease and multiple sclerosis.  Mult Scler. 2006;  12 S157
• 43 Kim K K. NMO-IgG and opticospinal multiple sclerosis and idiopathic recurrent myelitis.  Mult Scler. 2006;  12 S157
• 44 Nakashima I, Fujihara K, Miyazawa I et al.. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG.  J Neurol Neurosurg Psychiatry. 2006;  77 1073-1075
• 45 Marignier R, De Seze J, Durand-Dubief F et al.. NMO-IgG: a French experience.  Mult Scler. 2006;  12 S4
• 46 Amiry-Moghaddam M, Ottersen O P. The molecular basis of water transport in the brain.  Nat Rev Neurosci. 2003;  4 991-1001
• 47 Frigeri A, Gropper M A, Turck C W, Verkman A S. Immunolocalization of the mercurial-insensitive water channel and glycerol intrinsic protein in epithelial cell plasma membranes.  Proc Natl Acad Sci USA. 1995;  92 4328-4331
• 48 Nicchia G P, Nico B, Camassa L M et al.. The role of aquaporin-4 in the blood-brain barrier development and integrity: studies in animal and cell culture models.  Neuroscience. 2004;  129 935-945
• 49 Manley G T, Fujimura M, Ma T et al.. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke.  Nat Med. 2000;  6 159-163
• 50 Saadoun S, Papadopoulos M C, Davies D C et al.. Aquaporin-4 expression is increased in oedematous human brain tumours.  J Neurol Neurosurg Psychiatry. 2002;  72 262-265
• 51 Vajda Z, Pedersen M, Fuchtbauer E M et al.. Delayed onset of brain edema and mislocalization of aquaporin-4 in dystrophin-null transgenic mice.  Proc Natl Acad Sci USA. 2002;  99 13131-13136
• 52 Lehmann G L, Gradilone S A, Marinelli R A. Aquaporin water channels in central nervous system.  Curr Neurovasc Res. 2004;  1 293-303
• 53 Aoki K, Uchihara T, Tsuchiya K et al.. Enhanced expression of aquaporin 4 in human brain with infarction.  Acta Neuropathol. 2003;  106 121-124
• 54 Warth A, Mittelbronn M, Wolburg H. Redistribution of the water channel protein aquaporin-4 and the K + channel protein Kir4.1 differs in low- and high-grade human brain tumors.  Acta Neuropathol. 2005;  109 418-426
• 55 Weinshenker B G, O'Brien P C, Petterson T M et al.. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.  Ann Neurol. 1999;  46 878-886
• 56 Cree B A, Lamb S, Morgan K et al.. An open label study of the effects of rituximab in neuromyelitis optica.  Neurology. 2005;  64 1270-1272
• 57 Misu T, Fujihara K, Nakashima I et al.. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica.  Neurology. 2005;  65 1479-1482
• 58 Hinson S R, Pittock S J, Lucchinetti C F et al.. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.  Neurology. 2007;  69 2221-2231
• 59 April R S, Vansonnenberg E. A case of neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus. Clinicopathologic report and review of the literature.  Neurology. 1976;  26 1066-1070
• 60 Kinney E L, Berdoff R L, Rao N S, Fox L M. Devic's syndrome and systemic lupus erythematosus: a case report with necropsy.  Arch Neurol. 1979;  36 643-644
• 61 Mochizuki A, Hayashi A, Hisahara S, Shoji S. Steroid-responsive Devic's variant in Sjogren's syndrome.  Neurology. 2000;  54 1391-1392
• 62 de Seze J, Stojkovic T, Breteau G et al.. Acute myelopathies: clinical, laboratory and outcome profiles in 79 cases.  Brain. 2001;  124 1509-1521
• 63 Krishnan A V, Halmagyi G M. Acute transverse myelitis in SLE.  Neurology. 2004;  62 2087
• 64 Tellez-Zenteno J F, Remes-Troche J M, Negrete-Pulido R O, Davila-Maldonado L. Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging in six cases.  Lupus. 2001;  10 851-856
• 65 Im C Y, Kim S S, Kim H K. Bilateral optic neuritis as first manifestation of systemic lupus erythematosus.  Korean J Ophthalmol. 2002;  16 52-58
• 66 Hummers L K, Krishnan C, Casciola-Rosen L et al.. Recurrent transverse myelitis associated with anti-Ro (SSA) autoantibodies.  Neurology. 2004;  62 147-149
• 67 Lehnhardt F G, Impekoven P, Rubbert A et al.. Recurrent longitudinal myelitis as a primary manifestation of SLE.  Neurology. 2004;  63 1976
• 68 Pittock S J, Lennon V A, Wingerchuk D M et al.. The prevalence of non-organ-specific autoantibodies and NMO-IgG in neuromyelitis optica (NMO) and related disorders.  Neurology. 2006;  66 A307
• 69 Weinshenker B G, De Seze J, Vermersch P et al.. The relationship between neuromyelitis optica and systemic autoimmune disease.  Neurology. 2006;  66 A380
• 70 Pittock S J, Weinshenker B G, Wingerchuk D et al.. Autoimmune neurological accompaniments of neuromyelitis optica (NMO).  Ann Neurol. 2006;  60 S41
• 71 Furukawa Y, Yoshikawa H, Yachie A, Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population.  Eur J Neurol. 2006;  13 655-658
• 72 Kister I, Gulati S, Boz C et al.. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy.  Arch Neurol. 2006;  63 851-856
• 73 Antoine J C, Camdessanche J P, Absi L, Lassablière F, Féasson L. Devic disease and thymoma with anti-central nervous system and antithymus antibodies.  Neurology. 2004;  62 978-980
• 74 Wingerchuk D M, Weinshenker B G. Neuromyelitis optica.  Curr Treat Options Neurol. 2005;  7 173-182
• 75 Keegan M, Pineda A A, McClelland R L et al.. Plasma exchange for severe attacks of CNS demyelination: predictors of response.  Neurology. 2002;  58 143-146
• 76 Falcini F, Trapani S, Ricci L et al.. Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment.  Rheumatology (Oxford). 2006;  45 913-915
• 77 Weinstock-Guttman B, Ramanathan M, Lincoff N et al.. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).  Arch Neurol. 2006;  63 957-963
• 78 Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).  Can J Neurol Sci. 2004;  31 265-267
• 79 Noseworthy J, Miller D, Compston A. Disease-modifying treatments in multiple sclerosis. In: Compston A, Confavreaux C, Lassmann H. et al. McAlpine's Multiple Sclerosis. 4th ed. London; Churchill Livingston 2005: 729-802
• 80 Pittock S J, Weinshenker B G, Wijdicks E F. Mechanical ventilation and tracheostomy in multiple sclerosis.  J Neurol Neurosurg Psychiatry. 2004;  75 1331-1333